Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anna Kanerva

Showing results (81-90 of 124) with videos related to

Pageof 13
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 22, 2002
Targeting adenovirus to the serotype 3 receptor increases gene transfer efficiency to ovarian cancer cellsAnna Kanerva, Galina V Mikheeva, Victor Krasnykh, et al.
Cancer Research|March 8, 2012
Immune response is an important aspect of the antitumor effect produced by a CD40L-encoding oncolytic adenovirusIulia Diaconu, Vincenzo Cerullo, Mari L M Hirvinen, et al.
Cancer Gene Therapy|April 30, 2003
Replication of an integrin targeted conditionally replicating adenovirus on primary ovarian cancer spheroidsJohn T Lam, Gerd J Bauerschmitz, Anna Kanerva, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 15, 2010
Targeted chemotherapy for head and neck cancer with a chimeric oncolytic adenovirus coding for bifunctional suicide protein FCU1João D Dias, Ilkka Liikanen, Kilian Guse, et al.
Cancer Gene Therapy|September 13, 2020
Ad5/3 is able to avoid neutralization by binding to erythrocytes and lymphocytesSadia Zafar, Dafne Carolina Alves Quixabeira, Tatiana Viktorovna Kudling, et al.
Oncoimmunology|January 27, 2022
Local therapy with an engineered oncolytic adenovirus enables antitumor response in non-injected melanoma tumors in mice treated with aPD-1Dafne C A Quixabeira, Victor Cervera-Carrascon, Joao M Santos, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|February 25, 2003
A canine conditionally replicating adenovirus for evaluating oncolytic virotherapy in a syngeneic animal modelAkseli Hemminki, Anna Kanerva, Eric J Kremer, et al.
Cancer Research|March 13, 2002
Treatment of ovarian cancer with a tropism modified oncolytic adenovirusGerd J Bauerschmitz, John T Lam, Anna Kanerva, et al.
The Journal of Gene Medicine|October 20, 2004
Inter-patient variation in efficacy of five oncolytic adenovirus candidates for ovarian cancer therapyJohn T Lam, Anna Kanerva, Gerd J Bauerschmitz, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|August 30, 2003
Enhanced therapeutic efficacy for ovarian cancer with a serotype 3 receptor-targeted oncolytic adenovirusAnna Kanerva, Kurt R Zinn, Tandra R Chaudhuri, et al.
Pageof 13

Showing results (81-90 of 124) with videos related to

Sort By:
Pageof 13
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 22, 2002
Targeting adenovirus to the serotype 3 receptor increases gene transfer efficiency to ovarian cancer cellsAnna Kanerva, Galina V Mikheeva, Victor Krasnykh, et al.
Cancer Research|March 8, 2012
Immune response is an important aspect of the antitumor effect produced by a CD40L-encoding oncolytic adenovirusIulia Diaconu, Vincenzo Cerullo, Mari L M Hirvinen, et al.
Cancer Gene Therapy|April 30, 2003
Replication of an integrin targeted conditionally replicating adenovirus on primary ovarian cancer spheroidsJohn T Lam, Gerd J Bauerschmitz, Anna Kanerva, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 15, 2010
Targeted chemotherapy for head and neck cancer with a chimeric oncolytic adenovirus coding for bifunctional suicide protein FCU1João D Dias, Ilkka Liikanen, Kilian Guse, et al.
Cancer Gene Therapy|September 13, 2020
Ad5/3 is able to avoid neutralization by binding to erythrocytes and lymphocytesSadia Zafar, Dafne Carolina Alves Quixabeira, Tatiana Viktorovna Kudling, et al.
Oncoimmunology|January 27, 2022
Local therapy with an engineered oncolytic adenovirus enables antitumor response in non-injected melanoma tumors in mice treated with aPD-1Dafne C A Quixabeira, Victor Cervera-Carrascon, Joao M Santos, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|February 25, 2003
A canine conditionally replicating adenovirus for evaluating oncolytic virotherapy in a syngeneic animal modelAkseli Hemminki, Anna Kanerva, Eric J Kremer, et al.
Cancer Research|March 13, 2002
Treatment of ovarian cancer with a tropism modified oncolytic adenovirusGerd J Bauerschmitz, John T Lam, Anna Kanerva, et al.
The Journal of Gene Medicine|October 20, 2004
Inter-patient variation in efficacy of five oncolytic adenovirus candidates for ovarian cancer therapyJohn T Lam, Anna Kanerva, Gerd J Bauerschmitz, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|August 30, 2003
Enhanced therapeutic efficacy for ovarian cancer with a serotype 3 receptor-targeted oncolytic adenovirusAnna Kanerva, Kurt R Zinn, Tandra R Chaudhuri, et al.
Pageof 13